biologic

Pentacel

Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine

Loss of exclusivityJune 2020projected — 12-year biologic exclusivity estimate
CompanySanofi Vaccines Canada Ltd.

Drug detail

Brand namePentacel
Active ingredientDiphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine
Strength0.5ML
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalJune 2008
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Pentacel patent cliff — loss of exclusivity June 2020 | CliffBio